A phase II study of mitozolomide in metastatic transitional cell carcinoma of the bladder.
Blackledge
G
G
Department of Medicine, Queen Elizabeth Hospital, Birmingham, U.K.
Roberts
J T
JT
Kaye
S
S
Taylor
R
R
Williams
J
J
de Stavola
B
B
Uscinska
B
B
D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002295:Carcinoma, Transitional Cell / Q000188:drug therapy*; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D007970:Leukopenia / Q000139:chemically induced; D008297:Male; D008875:Middle Aged; D009588:Nitrogen Mustard Compounds / Q000009:adverse effects / Q000627:therapeutic use*; D013921:Thrombocytopenia / Q000139:chemically induced; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy*
D000970:Antineoplastic Agents; D009588:Nitrogen Mustard Compounds; C040369:mitozolomide